問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Family Medicine

Division of General Internal Medicine

Division of Endocrinology

Division of Cardiovascular Diseases

更新時間：2023-09-19

林文元Lin, Wen-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D10648@mail.cmuh.org.tw

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林文元

China Medical University Hospital

Division of Family Medicine

List

28Cases

2024-09-01 - 2026-09-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2021-04-01 - 2024-12-03

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2023-06-16 - 2024-05-15

Phase III

Completed
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

  • Condition/Disease

    Obesity、 Overweight、 Knee Pain Chronic、 Knee Osteoarthritis、 Obstructive Sleep Apnea

  • Test Drug

    LY3437943

Participate Sites
4Sites

Recruiting4Sites

2023-09-15 - 2025-10-22

Phase III

Completed
Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight and obesity (STEP 12)

  • Condition/Disease

    overweight and obesity

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2024-11-05 - 2027-02-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2022-11-01 - 2027-02-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2024-01-01 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2013-04-01 - 2015-06-30

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Aleglitazar (RO0728804)

Participate Sites
3Sites

Terminated3Sites

2021-07-15 - 2021-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-09-01 - 2021-05-31

Phase I

A phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of UB-612 vaccine in healthy adult volunteers

  • Condition/Disease

    Prevent COVID-19 infection

  • Test Drug

    UB-612

Participate Sites
1Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Infectious Disease

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB